• Manon Dubois, Camille Ardin, Fanny André, Arnaud Scherpereel, and Laurent Mortier.
• Service de dermatologie, CHU Lille, Lille, France.
• Med Sci (Paris). 2019 Dec 1; 35 (12): 937-945.

AbstractImmunotherapy represents a major paradigm shift, as the treatment no longer directly targets tumor cells, but the patient him/herself, in order to restore an effective anti-tumor immunity. This article illustrates the growing place of immune checkpoint inhibitors in the available therapeutic options, by focusing on two cancers with poor outcome: metastatic melanoma and metastatic non-small cell lung cancer (NSCLC), against which Immune checkpoints inhibitors now occupy a central place. Many questions remain unresolved, such as the search for markers predicting a good response to treatment, which would allow the selection of responder patients. Numerous trials are in progress, evaluating the relevance of these new molecules at earlier stages of the disease (adjuvant and neoadjuvant strategies) and their place in combined strategies (associated with chemotherapy, targeted therapies, and other types of immunotherapy).© 2019 médecine/sciences – Inserm.

28 keywords...

hide…